Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Engel Law PLLC is investigating whether fair value to Concert shareholders will result from the proposed sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharma for $8.00 per share plus a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Concert Pharmaceuticals, Inc.

MM slash DD slash YYYY